Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 23, 2004American Journal of HematologyOpen Access

Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP)

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAfaq AhmadServices Institute of Medical SciencesAAAnita AggarwalGeorge Washington UniversityDSDaya Nand SharmaAll India Institute of Medical Sciences Raipur

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ahmad et al. (2004) studied this question.

synapsesocial.com/papers/6a96e2c10f79e4f014b31144https://doi.org/10.1002/ajh.20166
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical Use of a Rapid Collagen Binding Assay for von Willebrand Factor Cleaving Protease in Patients with Thrombotic Thrombocytopenic Purpura2002 · 44 citations
  2. 2Unusually Large Plasma Factor VIII: von Willebrand Factor Multimers in Chronic Relapsing Thrombotic Thrombocytopenic Purpura1982 · 1,118 citations
  3. 3Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab2000 · 60 citations
  4. 4Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion1996 · 792 citations
  5. 5Treatment of Thrombotic Thrombocytopenic Purpura With Vincristine1982 · 94 citations